New York State Common Retirement Fund Sells 1,000 Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO)

New York State Common Retirement Fund reduced its position in Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 8.3% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 11,075 shares of the medical research company's stock after selling 1,000 shares during the period. New York State Common Retirement Fund's holdings in Bio-Rad Laboratories were worth $3,638,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. Venturi Wealth Management LLC boosted its holdings in shares of Bio-Rad Laboratories by 2,175.0% during the fourth quarter. Venturi Wealth Management LLC now owns 91 shares of the medical research company's stock worth $30,000 after purchasing an additional 87 shares during the period. Gladius Capital Management LP acquired a new stake in shares of Bio-Rad Laboratories during the third quarter worth approximately $32,000. Asset Planning Inc acquired a new stake in shares of Bio-Rad Laboratories during the fourth quarter worth approximately $33,000. UMB Bank n.a. boosted its holdings in shares of Bio-Rad Laboratories by 41.6% during the fourth quarter. UMB Bank n.a. now owns 109 shares of the medical research company's stock worth $36,000 after purchasing an additional 32 shares during the period. Finally, Point72 Hong Kong Ltd acquired a new stake in shares of Bio-Rad Laboratories during the third quarter worth approximately $55,000. 65.24% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on BIO. Wells Fargo & Company reduced their target price on shares of Bio-Rad Laboratories from $360.00 to $345.00 and set an "equal weight" rating for the company in a research note on Wednesday, February 12th. Royal Bank of Canada restated an "outperform" rating and issued a $481.00 price objective on shares of Bio-Rad Laboratories in a research note on Tuesday, January 14th. Finally, StockNews.com cut shares of Bio-Rad Laboratories from a "buy" rating to a "hold" rating in a research note on Monday, February 17th. Three analysts have rated the stock with a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $395.20.

Bio-Rad Laboratories Stock Performance

BIO stock traded down $8.91 on Monday, reaching $256.25. 267,048 shares of the company were exchanged, compared to its average volume of 232,744. Bio-Rad Laboratories, Inc. has a 12 month low of $256.12 and a 12 month high of $387.99. The stock's fifty day moving average price is $325.57 and its 200 day moving average price is $332.16. The firm has a market capitalization of $7.18 billion, a PE ratio of -3.94 and a beta of 0.90. The company has a debt-to-equity ratio of 0.18, a current ratio of 6.48 and a quick ratio of 4.85.

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last announced its quarterly earnings results on Thursday, February 13th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.86 by $0.04. Bio-Rad Laboratories had a negative net margin of 71.86% and a positive return on equity of 3.90%. On average, research analysts anticipate that Bio-Rad Laboratories, Inc. will post 10.81 EPS for the current fiscal year.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.